Clinical Question

In children presenting with acute severe asthma, does intravenous aminophylline improve meaningful clinical outcomes compared to standard therapy?

⸻

Background

IV aminophylline has historically been used as a second-line infusion in severe paediatric asthma. However, contemporary escalation strategies increasingly prioritise:

• Oxygen

• High-dose nebulised salbutamol

• Systemic corticosteroids

• IV magnesium sulphate

This raises the question: does aminophylline still offer incremental benefit?

⸻

The Evidence Reviewed

A systematic review published in Archives of Disease in Childhood analysed:

• 9 randomised controlled trials

• 466 children

• Standard therapy ± IV aminophylline

Outcomes assessed:

• Asthma severity scores

• Length of stay

• Admission rates

• PICU admission

• Intubation rates

• Adverse effects

⸻

Key Findings

No significant benefit in:

• Speed of clinical improvement

• Admission rates

• PICU transfer

• Intubation rates

• Length of hospital stay

Significant increase in adverse effects:

• Nausea and vomiting (3–5x higher)

• Headache

• Tremor

• Irritability

• Arrhythmias

Overall: No improvement in meaningful outcomes, with increased morbidity.

⸻

Important Caveat

A 1998 study (Young & South) suggested possible benefit in the most critically unwell, treatment-refractory children, including:

• Reduced duration of intubation

• Potential improvement in lung function

This suggests a potential narrow rescue-therapy window.

⸻

Implications for Paediatric Emergency Practice (2025)

Current best evidence supports:

1. Oxygen

2. Nebulised salbutamol

3. Systemic corticosteroids

4. IV magnesium

5. Structured escalation planning

IV aminophylline should be considered:

• A rescue therapy of last resort

• Not routine second-line treatment

⸻

Take-Home Message

IV aminophylline has historical presence but limited modern evidence of benefit. For most children with acute severe asthma, it increases adverse effects without improving outcomes.

Its role in 2025: rare, selective, and critically contextual.

In this episode we talk to Dr Etimbuk Umana, the lead author of the FIDO study looking at the management of febrile infants in the Emergency Department. FIDO is a PERUKI sponsored study and was recently published in The Lancet: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00540-6/fulltext

We talk to Dr Tom Jackson about his article in Archives of Disease in Childhood looking at the use of Dexmedetomidine as a sedative agent fro children undergoing MRI scans in a district general hospital. Is it better the NICE recommended medications? Article can be found here: https://adc.bmj.com/content/early/2022/03/10/archdischild-2021-322734

There are so many infant milks and formulae available that it can be confusing to healthcare professionals, let alone parents. Where did they come from, what do they contain and what about specialist prescription-only formulae. Host Dr Ashley Reece takes a deep dive into all these issues with our special guest Bahee Van de Bor - dietician and spokesperson of the British Dietetic Association. You can explore more about Bahee's work at www.ukkidsnutrition.com

We are all busy professionals with lots to do in a very limited amount of time, so why should we be concerned about climate change? That's nothing to do with paediatricians surely? Dr Katie Knight explains why its everything to do with paediatricians and the number one public health emergency for our patients not just tomorrow but today.

We are joined by Dr Lucie Etheridge and Julia Avery to discuss their recent article in the October 2021 edition of 'Archives of Disease in Childhood' looking at whether magnesium supplementation is helpful in adolescents with migraine.

We are really proud to introduce another episode from our Advanced Practitioner team, this time from the ANNPs. Rhian Smith, Becky Joyce and Dr Vicky Payne discuss the past, present and future of Advanced Neonatal Nurse Practitioners in the UK.